Becton Dickinson & Co
BDX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$415.00 | Xlyzqht | Zgtzhzb |
Strong Veritor Demand Sets BD for Strong 2021
Business Strategy and Outlook
2020 was a challenging year for Becton, Dickinson, or BD. While the company had seen a modest uptick in revenue related to the coronavirus pandemic, many of its business lines tied to hospital admissions got crushed. In addition, BD suffered from a major self-inflicted wound--a recall of its infusion pump Alaris. Combined with a paclitaxel setback to its vascular portfolio from a prior year, the company's execution has been far from ideal.